Centrient Pharmaceuticals Archives

Home / Posts tagged Centrient Pharmaceuticals

Centrient Pharmaceuticals Announces its Achievement of a Significant Milestone in the Clean Production of Antibiotics

Rijswijk, The Netherlands, May 19 (Korea Bizwire) – Summary Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistance The company is the first to publicly announce that Its entire supply chain of oral antibiotics – including its own [...]

Centrient Pharmaceuticals Boosting Statins API Manufacturing Capacity

Rotterdam, The Netherlands, June 21 (Korea Bizwire) – Summary: Centrient Pharmaceuticals has started production at its newly built statins API manufacturing unit in Toansa, India. With this expansion the company is doubling its production capacity of Atorvastatin and Rosuvastatin, meeting the increased demand for its high-quality uniquely produced statins. Centrient Pharmaceuticals’ statins are one of [...]

Centrient Pharmaceuticals to Acquire Astral SteriTech, Expanding its Product Portfolio with Sterile Injectable Antibiotic Finished Dosage Forms

Rotterdam, the Netherlands, Feb. 15 (Korea Bizwire) – Centrient Pharmaceuticals (“Centrient”), the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the signing of an agreement for the acquisition of Astral SteriTech Private Limited (“Astral SteriTech”), a leading international manufacturer specialised in sterile antibiotic injectable finished dosage forms. With the acquisition of Astral SteriTech, Centrient strengthens [...]

Centrient Pharmaceuticals Initiates a Second Patent Litigation in India Against Dalas Biotech Limited

ROTTERDAM, The Netherlands, Oct. 18 (Korea Bizwire) — Centrient Pharmaceuticals announced that on October 14th 2019, its wholly owned subsidiary, Centrient Pharmaceuticals India Private Limited, filed a second lawsuit against Dalas Biotech Limited in the High Court of Delhi in New Delhi, India for patent infringement of Indian Patent Number 318914. This patent, which is owned [...]

Centrient Pharmaceuticals Initiates Patent Litigation in India Against Dalas Biotech Limited

ROTTERDAM, Holland, May 1 (Korea Bizwire) — Centrient Pharmaceuticals announced that on April 25, 2019, its wholly owned subsidiary, Centrient Pharmaceuticals India Private Limited, filed a lawsuit against Dalas Biotech Limited in the High Court of Delhi in New Delhi, India for patent infringement of Indian Patent Number 247301. This patent, which is owned by [...]

The Delhi High Court in India Has Issued an Injunction, Restraining Sinopharm Weiqida from Exporting Its “Amoxycillin Trihydrate” Product to India, as It Infringes the Patent of Centrient Pharmaceuticals

ROTTERDAM, the Netherlands, Feb. 19 (Korea Bizwire) — Centrient Pharmaceuticals (“Centrient”), the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals, announced that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceuticals and Sinopharm India, restricting the export and/or import into India of its active [...]

DSM Sinochem Pharmaceuticals Announces its New Name – Centrient Pharmaceuticals

ROTTERDAM, Netherlands, Dec. 10 (Korea Bizwire) — Effective December 10, 2018 Centrient Pharmaceuticals is the new name for DSM Sinochem Pharmaceuticals, the leading manufacturer of beta-lactam antibiotics and a provider of next-generation statins and anti-fungals. The new name has been chosen to reflect the company’s key contribution to modern healthcare, and marks the next phase [...]